Markets:

Overview

News

Currencies

International

Treasuries

Bristol-Myers Squibb (NY:BMY)

57.12 +1.73 (+3.11%)

Streaming Delayed Price Updated: 12:36 PM EDT, Jun 26, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2

...

30 31 32 33 34 35 36 37 38

...

90 91 Next >

2 No-Brainer Dividend Stocks You Can Buy With $100 in June ↗

June 03, 2024

This pair of high-yield dividend payers offer yields near 6% and a chance for steady payout raises in the years to come.

Via The Motley Fool

KRAZATI (adagrasib) Demonstrated Statistically Significant Improvement in Progression-Free Survival in Patients with Pretreated Locally Advanced or Metastatic KRASG12C-Mutated Non-Small Cell Lung Cancer

June 01, 2024

From Bristol Myers Squibb

Via Business Wire

6% Yield Bristol Myers Squibb Value Trap Or Long-Term Opportunity? ↗

May 31, 2024

BMY is offering a 6% yield and trading for less than 9 times earnings.

Via Talk Markets

FDA Expands Approval For Bristol Myers Squibb's Breyanzi, Making CAR T Cell Therapy Available For Broadest Range Of B-Cell Malignancies ↗

May 31, 2024

FDA approves Bristol Myers Squibb's Breyanzi (lisocabtagene maraleucel) for relapsed or refractory mantle cell lymphoma, marking its fourth non-Hodgkin lymphoma subtype indication.

Via Benzinga

Bristol-Myers Squibb's Options: A Look at What the Big Money is Thinking ↗

May 30, 2024

Via Benzinga

(BMY) - Analyzing Bristol-Myers Squibb's Short Interest ↗

May 23, 2024

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

May 31, 2024

Via Benzinga

U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Breyanzi as a New CAR T Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma

May 30, 2024

From Bristol Myers Squibb

Via Business Wire

7 Underappreciated Stocks With 25% Return Potential in 2024 ↗

May 30, 2024

Each of these underappreciated stocks is expected to provide 25%+ returns this year, which is reason enough to pay attention.

Via InvestorPlace

May 23, 2024

This top pharma stock has fallen too far.

Via The Motley Fool

Spotlight on Bristol-Myers Squibb: Analyzing the Surge in Options Activity ↗

May 21, 2024

Via Benzinga

Are Boomers Crashing The Economy Or Saving It? Why Investors Are Perplexed And What You Can Do To Prepare ↗

May 29, 2024

Mass retirement of boomers could have major economic impact. Experts anticipate both risks and opportunities from the largest wealth transfer in history.

Via Benzinga

Topics Economy Retirement

Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma

May 29, 2024

From Bristol Myers Squibb

Via Business Wire

10 Health Care Stocks With Whale Alerts In Today's Session ↗

May 28, 2024

Via Benzinga

Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 4% Dividend Yields ↗

May 28, 2024

Via Benzinga

3 Blue-Chip Stocks to Buy at 52-Week Lows in May ↗

May 27, 2024

These three blue-chip stocks at a 52-week low could provide investors with a good opportunity to open a new position or double an old one.

Via InvestorPlace

S&P 500 Earnings Dashboard 24Q1 - Saturday, May 25 ↗

May 25, 2024

Of the 480 companies in the S&P 500 that have reported earnings to date for 24Q1, 77.9% reported above analyst expectations. This compares to a long-term average of 66%.

Via Talk Markets

Topics Stocks

Retail Earnings & Consumer Spending: A Closer Look ↗

May 25, 2024

The U.S. economy is chugging along, with growth moderately decelerating under the Fed’s tight monetary policy. Most of the Q1 earnings season is behind us, with results from 481 S&P 500 companies...

Via Talk Markets

Topics Economy Stocks

10 Health Care Stocks With Whale Alerts In Today's Session ↗

May 24, 2024

Via Benzinga

What's Going On With Mid-Cap Cancer-Focused Verastem Oncology Stock On Friday? ↗

May 24, 2024

Verastem Oncology reports promising initial results from the RAMP 205 trial with an 83% ORR for avutometinib and defactinib in metastatic pancreatic cancer. FDA submission for recurrent KRAS mutant...

Via Benzinga

Bonds Break Down And Send Everyone To Cash ↗

May 23, 2024

This situation is where the danger, the opportunity, and the action are right now.

Via Talk Markets

Bristol Myers Squibb to Present Data at ASCO & EHA from More Than 130 Studies Across 25 Diseases Supporting Expansion into New Indications, Demonstrating Long-Term Survival, and Highlighting Novel Modalities and Research Platforms

May 23, 2024

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb to Present Data at the 2024 American Society of Clinical Psychopharmacology Annual Meeting

May 23, 2024

From Bristol Myers Squibb

Via Business Wire

Hawaii Court Rules Against Bristol Myers, Sanofi In Blood Clot Drug Case, Increases Liability To $916M ↗

May 22, 2024

A Hawaii judge has ordered Bristol Myers Squibb and Sanofi to pay $916 million for not warning non-white patients about the health risks of their blood thinner Plavix. The ruling follows a previous...

Via Benzinga

Bristol Myers Squibb Announces 10-Year Strategy to Reach More Patients in Low- and Middle-Income Countries

May 22, 2024

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb, Taye Diggs and Schizophrenia Community Partner to Empower People with Schizophrenia Through Live Your PosSCZible Campaign

May 21, 2024

From Bristol Myers Squibb

Via Business Wire

1 Stock I Wouldn't Touch With a 10-Foot Pole ↗

May 21, 2024

This stock isn't as safe as it seems, and now isn't the time to dabble.

Via The Motley Fool

3 Bargain Stocks to Buy Now: May 2024 ↗

May 21, 2024

These bargain stocks to buy provide substantial upside since they are trading at a significant discount to their historical multiples.

Via InvestorPlace

Bristol Myers Squibb Announces Updated Action Date by the U.S. Food and Drug Administration for Subcutaneous Nivolumab (nivolumab and hyaluronidase)

May 21, 2024

From Bristol Myers Squibb

Via Business Wire

Large Cap Biopharmaceuticals Performance ↗

May 20, 2024

The biotech sector remains a laggard YTD as can be seen by the IBB.

Via Talk Markets

< Previous 1 2

...

30 31 32 33 34 35 36 37 38

...

90 91 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.